[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629719":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":41,"responsibleParty":60,"collaborators":63,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":25,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Longhua Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Western medicine treatment + Chaigui Longmu Ejiao Paste","EXPERIMENTAL","All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors\u002FARBs, and others.\n\nParticipants in the experimental arm received Chaigui Longmu Ejiao Paste 15 g orally twice daily (morning and evening) for 8 weeks.",[13],"Drug: Standard Western medicine treatment + Chaigui Longmu Ejiao Paste",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao","PLACEBO_COMPARATOR","All patients receive standard Western medical treatment prescribed by the attending physician in accordance with the latest clinical guidelines, including but not limited to antiplatelet agents, statins, β-blockers, ACE inhibitors\u002FARBs, and others.\n\nParticipants received Chaigui Longmu Paste without Ejiao 15 g orally twice daily (morning and evening) for 8 weeks.",[19],"Drug: Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","15 g orally twice daily",[9],null,{"type":22,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"Placebo Comparator: Standard Western medicine treatment + Chaigui Longmu Paste without Ejiao",[15],[30],{"name":31,"affiliation":32,"role":33},"Su yun Yuan, Ph.D","Shanghai University of Traditional Chinese Medicine","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Jia hong Jin, Ph.D","CONTACT","17321231717","021-64385700","370708790@qq.com",[42],{"facility":43,"status":25,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Longhua Hospital Shanghai University of Traditional Chinese Medicine","Shanghai","Shanghai Municipality","Xuhui District","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":57,"role":37,"phone":58,"phoneExt":25,"email":59},"Lili Yang, Ph.D","13816867654","lhtcmkyc@163.com",{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Suyun Yuan","Chief Physician",[64,65],{"name":32,"class":6},{"name":66,"class":67},"DongE E Jiao Coporation Limited","INDUSTRY","100629719","phase-2-chaigui-longmu-ejiao-paste-for-ischemic-heart-disease-100629719",false,"NCT07478328","Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","A Randomized, Double-Blind Clinical Trial of Chaigui Longmu Ejiao Paste in the Treatment of Ischemic Heart Disease With Internal and External Controls","Inclusion Criteria:\n\n1. Age 18-75 years, both sexes eligible;\n2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks;\n3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying\u002Fstabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages;\n4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of \"thoracic yang deficiency with heart vessel stasis\" (or \"chest yang insufficiency with heart meridian blood stasis\"), with primary symptoms: chest oppression\u002Fpain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings;\n5. Has signed the informed consent form and is willing to participate voluntarily in the study.\n\nExclusion Criteria:\n\n1. Acute coronary syndrome or patients requiring emergency revascularization;\n2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks;\n3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment);\n4. Severe heart failure (NYHA functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate;\n5. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × upper limit of normal, or creatinine \\> 1.5 × upper limit of normal);\n6. Known allergy to any component of the study formula;\n7. Women who are pregnant, lactating, or planning pregnancy;\n8. Patients who have participated in other clinical trials within the past 3 months;\n9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.","ALL","18 Years","75 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.",[86],"Ischemic Heart Disease","NOT_YET_RECRUITING","2026-03-13",{"date":90,"type":91},"2026-03-17","ACTUAL",{"date":93,"type":80},"2026-03-08",{"date":95,"type":80},"2028-12-31",{"name":5,"class":6},1]